BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 30118648)

  • 1. Next-generation sequencing reveals mutational accordance between cell-free DNA from plasma, malignant pleural effusion and ascites and directs targeted therapy in a gastric cancer patient.
    Zhou S; Xu B; Qi L; Zhu D; Liu B; Wei J
    Cancer Biol Ther; 2019; 20(1):15-20. PubMed ID: 30118648
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating tumor DNA profiling by next generation sequencing reveals heterogeneity of crizotinib resistance mechanisms in a gastric cancer patient with MET amplification.
    Du J; Wu X; Tong X; Wang X; Wei J; Yang Y; Chang Z; Mao Y; Shao YW; Liu B
    Oncotarget; 2017 Apr; 8(16):26281-26287. PubMed ID: 28460431
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Malignant pleural effusion supernatant is an alternative liquid biopsy specimen for comprehensive mutational profiling.
    Guo Z; Xie Z; Shi H; Du W; Peng L; Han W; Duan F; Zhang X; Chen M; Duan J; Lin J; Chen X; Lizaso AA; Han-Zhang H; He J; Yin W
    Thorac Cancer; 2019 Apr; 10(4):823-831. PubMed ID: 30779318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distinct profile of cell-free DNA in malignant pleural effusion of non-small cell lung cancer and its impact on clinical genetic testing.
    Yu Y; Qian J; Shen L; Ji W; Lu S
    Int J Med Sci; 2021; 18(6):1510-1518. PubMed ID: 33628109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improving diagnostic accuracy of identifying gastric cancer patients with peritoneal metastases: tumor-guided cell-free DNA analysis of peritoneal fluid.
    van der Sluis K; van Sandick JW; Vollebergh MA; van Dieren JM; Hugen N; Hartemink KJ; Veenhof AAFA; Verhoeven E; van den Berg JG; Snaebjornsson P; Noe M; van Wezel T; Boelens MC; Kodach LL
    Oncogene; 2024 Jun; 43(24):1877-1882. PubMed ID: 38654110
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic Profiling of Non-Small Cell Lung Cancer at Development of Resistance to First- or Second-Generation EGFR-TKIs by CAPP-Seq Analysis of Circulating Tumor DNA.
    Otsubo K; Sakai K; Takeshita M; Harada D; Azuma K; Ota K; Akamatsu H; Goto K; Horiike A; Kurata T; Nakagaki N; Nosaki K; Iwama E; Nakanishi Y; Nishio K; Okamoto I
    Oncologist; 2019 Aug; 24(8):1022-1026. PubMed ID: 31023862
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating Cell-Free Tumor DNA Analysis of 50 Genes by Next-Generation Sequencing in the Prospective MOSCATO Trial.
    Jovelet C; Ileana E; Le Deley MC; Motté N; Rosellini S; Romero A; Lefebvre C; Pedrero M; Pata-Merci N; Droin N; Deloger M; Massard C; Hollebecque A; Ferté C; Boichard A; Postel-Vinay S; Ngo-Camus M; De Baere T; Vielh P; Scoazec JY; Vassal G; Eggermont A; André F; Soria JC; Lacroix L
    Clin Cancer Res; 2016 Jun; 22(12):2960-8. PubMed ID: 26758560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cell-free DNA From Pleural Effusion Samples: Is It Right for Molecular Testing in Lung Adenocarcinoma?
    Mokánszki A; Bádon ES; Mónus A; Tóth L; Bittner N; Méhes G
    Pathol Oncol Res; 2021; 27():613071. PubMed ID: 34257581
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acquisition of Cabozantinib-Sensitive MET D1228N Mutation During Progression on Crizotinib in MET-Amplified Triple-Negative Breast Cancer.
    Parsons BM; Meier DR; Richmond CS; Gurda GT; Lofgren KA; Burkard ME; Deming DA; Kenny PA
    Clin Breast Cancer; 2020 Aug; 20(4):e433-e438. PubMed ID: 32234363
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of an optimal protocol for molecular profiling of tumor cells in pleural effusions at single-cell level.
    Nakamura IT; Ikegami M; Hasegawa N; Hayashi T; Ueno T; Kawazu M; Yagishita S; Goto Y; Shinno Y; Kojima Y; Takamochi K; Takahashi F; Takahashi K; Mano H; Kohsaka S
    Cancer Sci; 2021 May; 112(5):2006-2019. PubMed ID: 33484069
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cell-free DNA is abundant in ascites and represents a liquid biopsy of ovarian cancer.
    Werner B; Yuwono N; Duggan J; Liu D; David C; Srirangan S; Provan P; ; DeFazio A; Arora V; Farrell R; Lee YC; Warton K; Ford C
    Gynecol Oncol; 2021 Sep; 162(3):720-727. PubMed ID: 34454680
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antitumor action of the MET tyrosine kinase inhibitor crizotinib (PF-02341066) in gastric cancer positive for MET amplification.
    Okamoto W; Okamoto I; Arao T; Kuwata K; Hatashita E; Yamaguchi H; Sakai K; Yanagihara K; Nishio K; Nakagawa K
    Mol Cancer Ther; 2012 Jul; 11(7):1557-64. PubMed ID: 22729845
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic Profiling of Cell-Free DNA From Pleural Effusion in Advanced Lung Cancer as a Surrogate for Tumor Tissue and Revealed Additional Clinical Actionable Targets.
    Tu HY; Li YS; Bai XY; Sun YL; Zheng MY; Ke EE; Liao RQ; Jiang BY; Lin JX; Huang J; Xu BF; Yang JJ; Zhang XC; Zhou Q; Wang BC; Chen HJ; Tong X; Yu R; Wu X; Zhu D; Wu YL
    Clin Lung Cancer; 2022 Mar; 23(2):135-142. PubMed ID: 34645582
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of EGFR mutation status in malignant pleural effusion and plasma from patients with advanced lung adenocarcinoma.
    Son SM; Woo CG; Han HS; Lee KH; Lim YH; Lee OJ
    Clin Chem Lab Med; 2020 Aug; 58(9):1547-1555. PubMed ID: 32229655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cell-Free DNA from Ascites and Pleural Effusions: Molecular Insights into Genomic Aberrations and Disease Biology.
    Husain H; Nykin D; Bui N; Quan D; Gomez G; Woodward B; Venkatapathy S; Duttagupta R; Fung E; Lippman SM; Kurzrock R
    Mol Cancer Ther; 2017 May; 16(5):948-955. PubMed ID: 28468865
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of EGFR gene mutation status from pleural effusions and other body fluid specimens in patients with lung adenocarcinoma.
    Zhang P; Wu X; Tang M; Nie X; Li L
    Thorac Cancer; 2019 Dec; 10(12):2218-2224. PubMed ID: 31602787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted deep sequencing of cell-free DNA in serous body cavity fluids with malignant, suspicious, and benign cytology.
    Yang SR; Mooney KL; Libiran P; Jones CD; Joshi R; Lau HD; Stehr H; Berry GJ; Zehnder JL; Long SR; Kong CS; Kunder CA
    Cancer Cytopathol; 2020 Jan; 128(1):43-56. PubMed ID: 31751001
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detecting EGFR mutations and ALK/ROS1 rearrangements in non-small cell lung cancer using malignant pleural effusion samples.
    Yao Y; Peng M; Shen Q; Hu Q; Gong H; Li Q; Zheng Z; Xu B; Li Y; Dong Y
    Thorac Cancer; 2019 Feb; 10(2):193-202. PubMed ID: 30565433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic alterations and their clinical implications in gastric cancer peritoneal carcinomatosis revealed by whole-exome sequencing of malignant ascites.
    Lim B; Kim C; Kim JH; Kwon WS; Lee WS; Kim JM; Park JY; Kim HS; Park KH; Kim TS; Park JL; Chung HC; Rha SY; Kim SY
    Oncotarget; 2016 Feb; 7(7):8055-66. PubMed ID: 26811494
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Next-generation sequencing-based BRCA testing on cytological specimens from ovarian cancer ascites reveals high concordance with tumour tissue analysis.
    Fumagalli C; Rappa A; Casadio C; Betella I; Colombo N; Barberis M; Guerini-Rocco E
    J Clin Pathol; 2020 Mar; 73(3):168-171. PubMed ID: 31537627
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.